



# CLINICAL NUTRITION EXPERIMENTAL

Methodology and Basic Science

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.1</b>
●	<b>Editorial Board</b>	<b>p.1</b>
●	<b>Guide for Authors</b>	<b>p.6</b>



ISSN: 2352-9393

### DESCRIPTION

*Clinical Nutrition Experimental* is the peer-reviewed open-access official journal of [ESPEN, The European Society for Clinical Nutrition and Metabolism](#). With the aim to stimulate experimental research activities in the field of clinical nutrition, the journal welcomes the latest and most exciting experimental articles on methodology, nutrient physiology and metabolism, nutritional neurosciences, nutritional toxicities, nutritional immunology, nutrigenomics, molecular nutrition, vitamins, trace elements, antioxidants, genetics and microbiota. Completing the existing journals: [Clinical Nutrition](#) and [Clinical Nutrition ESPEN](#), CNX will promote methodology and basic science in the field of clinical nutrition.

### ABSTRACTING AND INDEXING

Directory of Open Access Journals (DOAJ)  
EMBASE/Excerpta Medica  
ScienceDirect  
Scopus  
FSTA (Food Science and Technology Abstracts)

### EDITORIAL BOARD

#### *Editor-in-Chief*

**P. Singer, MD**, Sackler School of Medicine, Institute for Nutrition Research, Tel Aviv University, Tel Aviv, Israel

#### *Managing Editor*

**J. A. Mays**, Dept. of Health and Kinesiology, Texas A&M University, College Station, Texas, USA

#### *Associate Editors*

**R. Barazzoni, MD, PhD**, University of Trieste, Trieste, Italy

**J. Bauer, MD, PhD**, Dept. of Internal Medicine/Geriatric Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany

**M. Coëffier, PhD**, Medical School, University of Rouen, Rouen, France

**N. Deutz, MD, PhD**, Dept. of Health and Kinesiology, Texas A&M University, College Station, Texas, USA

**J. Faintuch, MD, PhD**, Radiopharmacy Center, Universidade de São Paulo (USP), Sao Paulo, Brazil

**R. Koopman**, Centre for Muscle Research, Dept of Physiology, The University of Melbourne, Melbourne, Victoria, Australia

**V. Pisprasert, MD, PhD**, Division of Clinical Nutrition, Khon Kaen University, Khon Kaen, Thailand  
**O. Tirosh, PhD**, Inst. of Biochemistry, Food Science and Nutrition, Hebrew University of Jerusalem, Jerusalem, Israel  
**J. Y. Yu, PhD**, Chinese Academy of Medical Sciences, Beijing, China

**Editorial Advisory Board / ESPEN Faculty**

**M. Bahar**, Department of Anesthesia and Intensive Care, Istanbul University Cerrahpaşa Medical Faculty Hospital, Istanbul, Turkey  
**J. Baxter, PhD**, Scottish Home Parenteral Nutrition Managed Clinical Network, Ninewells Hospital and Medical School, Dundee, Scotland, UK  
**M. Berger, MD, PhD**, Dept. of Adult Critical Care Medicine and Burns Center, Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland  
**Y. Berner, MD**, Sackler Medical School, Tel Aviv University, Kfar-Saba, Israel  
**H. Biesalski, PhD**, Dept. of Biological Chemistry & Nutrition, Universität Hohenheim, Stuttgart, Germany  
**J. Bines, MD, FRACP**, Murdoch Childrens Research Institute, Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia  
**G. Biolo, MD, PhD**, Div. of internal medicine, Università di Trieste, Trieste, Italy  
**B. Bistrián, MD**, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA  
**G. Bodoky, MD, PhD**, Dept. of Surgery, Semmelweis University of Medicine, Budapest, Hungary  
**Y. Boirie, MD, PhD**, Lab. de Nutrition Humaine, Université d'Auvergne, Clermont-Ferrand, France  
**I. Bosaeus, MD, PhD**, Dept. of Clinical Nutrition, Göteborg University (Sahlgrenska University Hospital), Göteborg, Sweden  
**F. Bozzetti, MD**, Department of Surgery, Ospedale di Prato, Prato, Italy  
**M. Braga, MD**, Scientific Institute San Raffaele Hospital, Università Vita-Salute San Raffaele, Milan, Italy  
**I. Bretón**, Hospital General Universitario Gregorio Marañón, Madrid, Spain  
**A. Buchman, MD, MSPH**, Northwestern Medical Faculty Foundation, Chicago, Illinois, USA  
**R. Burgos Pelaez**, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain  
**E. Cabré, MD, PhD**, Dept. of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain  
**P. Calder, PhD**, Inst. of Human Nutrition, University of Southampton, Southampton, UK  
**M.E. Camilo, MD, PhD**, Inst. of Molecular Medicine, Universidade de Lisboa, Lisboa, Portugal  
**B. Campillo, MD**, Serv. de Rééducation Digestive, Hôpital Albert Chenevier, Créteil cedex, France  
**A. Campos, MD, PhD**, Div. of Liver Transplantation, Universidade Federal do Paraná (UFPR), Curitiba, Brazil  
**N. Cano, MD, PhD**, INRA de Clermont-Ferrand/Theix, Clermont-Ferrand, France  
**Y. Carpentier, MD**, L. Deloyers Laboratory of Experimental Surgery, Université Libre de Bruxelles (ULB), Brussels, Belgium  
**J. J. Carrero, PhD**, Karolinska Institutet, Stockholm, Sweden  
**T. Cederholm, MD, PhD**, Clinical Nutrition and Metabolism, Uppsala Universitet, Uppsala, Sweden  
**I. Chermesh**, Ramabm Medical Center, Faculty of Medicine, The Ruth and Bruce Rappaport, Israel Institute of Technology, Israel  
**M.I.T.D. Correia, MD, PhD**, Dept. of Surgery, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil  
**A. Cosslett, PhD, MRPharmS**, Dept. of Pharmaceutical Sciences, Cardiff University, Cardiff, UK  
**M. Cravo, MD, PhD**, Dept. of Gastroenterology, Instituto Português de Oncologia de Francisco Gentil, Lisbon, Portugal  
**C. Cuerda, MD, PhD**, Nutrition Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain  
**L. Cynober, PhD**, Clinical chemistry, Institut Cochin, Paris, France  
**E. Dárdai**, St. Stephan Hospital, Department of Anaesthesiology and Intensive Therapy, Budapest, Hungary  
**A. Davies, MD, FRACP**, The Alfred Intensive Care Unit, Melbourne, Victoria, Australia  
**J.P. de Bandt, PhD, PharmD**, Laboratoire de biologie de la nutrition, Université Paris Descartes, Paris, France  
**I. de Blaauw**, Dept. of Pediatric Surgery, Radboudumc, Nijmegen, Netherlands  
**P. Dechelotte, PhD, MD**, CHU. Dept. of Nutrition Unit, Université de Rouen, Mont-Saint-Aignan, France  
**C.H. Dejong, MD, PhD**, Dept. of Surgery, University Hospital Maastricht, Maastricht, Netherlands  
**S.J. Dudrick, MD**, Dept. of Surgery, St Mary's Hospital, Waterbury, Connecticut, USA  
**N. Elia, MD, BSc (Hons), FRCP**, Inst. of Human Nutrition, University of Southampton, Southampton, Scotland, UK  
**E. Fiaccadori, PhD, MD**, Dept. of Clinical Medicine, Nephrology and Prevention Sciences, Università degli Studi di Parma, Parma, Italy  
**É. Fontaine, MD, PhD**, Nutrition, CHU de Grenoble, Grenoble, France  
**A. Forbes, BSc, MD, FRCP, FHEA**, Department of Gastroenterology and Nutrition, University College Hospital, London, England, UK  
**X. Forceville, MD, PhD**, Centre Hospitalier de Meaux, MEAUX CEDEX, France  
**C. Fusch, MD**, Division of Neonatology, McMaster University, Hamilton, Ontario, Canada  
**M. Gassull, MD**, Health Sciences Research Institute, Germans Trias I Pujol, Badalona, Spain  
**L. Genton, MD**, Clin. Nutrition and Dietetics, Geneva University Hospitals, Genève, Switzerland  
**O. Genzel-Boroviczeny, MD**, Dr. von Hauner Children's Hospital Sches, Ludwig-Maximilians-Universität München (LMU), Munich, Germany  
**A. Gil Hernández, PhD**, Inst. of Nutrition and Food Technology, Universidad de Granada, Granada, Spain

**J Gomez Saez**, Endocrinology and Nutrition Service, Bellvitge University Hospital, Barcelona, Spain

**F. Gottrand, MD, PhD**, Jeanne de Flandre Children's Hospital, Centre Hospitalier et Universitaire de Lille, Lille, France

**O. G. Goulet, MD, PhD**, Department of paediatric gastroenterology, hepatology and nutrition, Hôpital Necker - Enfants Malades, Paris, France

**L. Gramlich, MD**, University of Alberta, Royal Alexandra Hospital, Edmonton, Canada

**E. Granot, MD**, Kaplan Medical Center, Hebrew University Hadassah Medical School, Rehovot, Israel

**R. Griffiths, MD, FRCP**, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

**R. Grimble, PhD**, Inst. of Human Nutrition, University of Southampton, Southampton, UK

**I. Grintescu, MD, PhD**, Emergency Clinical Hospital, Bucharest, Romania

**G. Guarnieri, MD**, Div. of internal medicine, Università di Trieste, Trieste, Italy

**D. Guttridge, PhD**, Coll. of Medicine, Sch. of Biomedical Science, The Ohio State University, Columbus, Ohio, USA

**G. Hardy, PhD, FRSC**, Fac. of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

**X. Hébuterne**, Le Centre Hospitalier Universitaire de Nice, Nice, France

**B. Heitmann, PhD**, Inst. of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark

**O. Hernell, MD, PhD**, Dept. of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden

**M. Holst, RN, MCN, PhD**, Ctr. for Nutrition and Bowel Disease, Aalborg Hospital, Aalborg, Denmark

**P. Howard, RD**, Nutrition and Dietetic Services, Bristol Royal Infirmary, Bristol, England, UK

**G. Iapichino, MD**, San Paolo Hospital, Università degli Studi di Milano, Milan, Italy

**O. Irtun**, University Hospital of North Norway, Tromsø, Norway

**K. Jeejeebhoy**, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada

**G. Jensen, MD, PhD**, Coll. Of Health and Human Development, Pennsylvania State University, University Park, Pennsylvania, USA

**P. Jeppesen, MD**, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

**C. Jonkers-Schuitema, RD**, Dietetic Department, Academic Medical Center, Amsterdam, Netherlands

**K. Joosten, PhD, MD**, Department of Paediatrics, subdivision Paediatric Intensive Care, Sophia Children's Hospital, Rotterdam, Netherlands

**F. Kalfarentzos, MD**, Sch. of Medicine, University of Patras, Patras, Greece

**S. Kilicturgay**, Uludag University, Turkey

**S. Klek, PhD, MD**, Stanley Dudrick's Memorial Hospital, Union Memorial Hospital, Skawina, Poland

**S. Kolacek**, Dept. of Gastroenterology, Zagreb Children's Hospital, Zagreb, Croatia

**B. Koletzko, MD, PhD**, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München (LMU), München, Germany

**R. Komsa-Penkova, PhD**, Dept. of chemistry and Bio-chemistry, University of Medicine Pleven, Pleven, Bulgaria

**J. Kondrup, MD, Dr Med Sci**, Dept. of Human Nutrition, University of Copenhagen, Frederiksberg, Denmark

**Z. Krznaric, MD, PhD**, Sch. of Medicine, Sveučilišta u Zagrebu, Zagreb, Croatia

**J. Ksiazek, MD, PhD**, Dept. of Gastroenterology, Hepatology and Nutrition, The Children's Memorial Health Inst., Warsaw, Poland

**A. Lapillonne, MD, PhD**, Hôpital Necker - Enfants Malades, Paris, France

**A. Laviano, MD, PhD**, Dipartimento di Medicina Clinica, Università di Roma

**M. Léon-Sanz**, Hospital 12 de Octubre, Madrid, Spain

**E. Lerebours, MD, PhD**, Serv. d'Hépatogastroentérologie et Nutrition, Université de Rouen, Rouen cedex, France

**B. Lindholm, MD, PhD**, Dept. of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden

**O. Ljungqvist, MD, PhD**, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden

**D. Lobo**, Faculty of Medicine & Health Sciences, Queen's Medical Centre, Nottingham, UK

**H. Lochs, MD**, Medizinische Universität Innsbruck, Innsbruck, Austria

**C. Löser**, Medical Department, Christian-Albrechts-University, Kiel, Germany

**Y. Luiking, PhD**, Gastrointestinal Research Unit, Universitair Medisch Centrum Utrecht (UMC Utrecht), Utrecht, Netherlands

**K. Lundholm**, Dept. of Surgery, Göteborg University (Sahlgrenska University Hospital), Göteborg, Sweden

**J. MacFie, PhD**, Combined Gastroenterology Unit, Scarborough Hospital, Scarborough, UK

**E. Mathus-Vliegen**, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands

**R. Meier, MD**, FMH Internal Medicine and Gastroenterology, Kantonsspital Liestal, Liestal, Switzerland

**J.C. Melchior, MD, PhD**, Département de médecine unité de nutrition, Raymond Poincaré Hospital, Garches, France

**K. Melzer**, Swiss Federal Institute of Sports, Macolin, Switzerland

**M. Merli, MD**, II Gastroenterologia, Università di Roma, Rome, Italy

**B. Messing, MD**, Hôpital Lariboisière, Paris, France

**W. Mihatsch, MD**, Dept. of Paediatrics, Deaconry Hospital, Schwaebisch Hall, Germany

**A. Mijan de la Torre**, Burgos University Hospital, Burgos, Spain

**J. Moreno**, Hospital 12 de Octubre, Madrid, Spain

**B. Morio**, INRA Research Centre of Clermont-Ferrand, Lyon, France

**S. Muhlebach**, Departement Pharmazeutische Wissenschaften, Basel Switzerland

**M. Muller**, Norwich Medical School, University of East Anglia, Norwich, United Kingdom  
**M. Muscaritoli**, Dept. of Clinical science, Università di Roma  
**G. Nitenberg, MD, PhD**, Private Practice, Paris, France  
**K. Norman**, Charite Research Group on Geriatrics, Berlin, Germany  
**I. Nyulasi**, Department of Nutrition and Dietetics, Alfred Health, Melbourne, Australia  
**J. Ockenga, MD**, Klinikum Bremen Mitte, Gesundheit Nord, Bremen, Germany  
**H. Ohyanagi**, Department of Surgery, Kinki University School of Medicine, Osaka, Japan  
**M. Pertkiewicz, MD**, Fac. of Nutritional and Metabolic, Medical University of Warsaw, Warsaw, Poland  
**C. Pichard, MD, PhD**, Nutrition Unit, Hôpitaux Universitaires de Genève, Geneva, Switzerland  
**M. Pirlich, MD**, PGD International GmbH, Elisabeth Protestant Hospital, Berlin, Germany  
**L. Pironi, MD**, Dept. of Clinical Medicine, Università di Bologna, Bologna, Italy  
**C. Pison, MD**, University Hospital of Grenoble, Université Joseph Fourier (Grenoble I), Grenoble, France  
**M. Plauth, MD**, Wound Center Dessau-Rosslau, Städtisches Klinikum Dessau, Dessau, Germany  
**J. Preiser, MD, PhD**, Dept. of General Intensive Care, Université de Liège (Centre Hospitalier), Liege, Belgium  
**P. Ravasco, MMSc, MD, PhD**, Unidade de Nutrição e Metabolismo, Universidade de Lisboa, Lisbon, Portugal  
**O. Riggio, MD**, Ctr. for Diagnosis and Treatment of Portal Hypertension, Sapienza Università di Roma, Rome, Italy  
**O. Rooyackers, PhD**, Dept. of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden  
**F. Rossi-Fanelli, MD**, Dept. of Clinical Medicine, Sapienza Università di Roma, Rome, Italy  
**E. Roth, PhD**, Dept. of Surgery, Medizinische Universität Wien, Vienna, Austria  
**G. Rozen, RD, PhD**, Dept. of Clinical Nutrition, Rambam Medical Center, Haifa, Israel  
**J. Shaffer**, Salford Royal, NHS Foundation Trust, Stott Lane, Salford, United Kingdom  
**R. Shamir, MD**, Schneider Children's Medical Center of Israel, Tel-Aviv University, Tel Aviv, Israel  
**A. Shenkin, MB, ChB, PHD, FRCP, FRCPath**, Dept. of Clinical Chemistry, University of Liverpool, Liverpool, UK  
**D. Silk, MD AGAF FRCP**, Northwick Park Hospital, Imperial College Healthcare NHS Trust, London, England, UK  
**L. Sobotka, MD, PhD**, Dept. of Social Medicine, Charles University, Hradec Kralove, Czech Republic  
**M. Soeters, MD, PhD**, Dep't of Endocrinology & Metabolism, Internal Medicine, Maastricht University Medical Center, Meibergdreef 9, Netherlands  
**Z. Stanga, MD**, Bern University Hospital, University of Bern, Bern, Switzerland  
**M. Staun**, Rigshospitalet, Copenhagen, Denmark  
**R. Stratton**, Inst. of Human Nutrition, University of Southampton, Southampton, Scotland, UK  
**H. Szajewska, MD**, Dept. of Paediatrics, Medical University of Warsaw, Warsaw, Poland  
**P. Sztanyai**, Department of Pediatrics, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic  
**K.A. Tappenden, PhD, RD**, Dept. of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA  
**L. Tappy, PhD**, Dept. of Physiology, Université de Lausanne, Lausanne, Switzerland  
**V. Teplan, MD**, Dept. of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic  
**P. Tesinsky, MD**, Dept. of Internal Medicine II, Charles University, Prague, Czech Republic  
**D. Teta, MD, PhD**, University Hospital, Université de Lausanne, Lausanne, Switzerland  
**J.P. Thissen, MD, PhD**, Div. of Diabetology and Nutrition, Université catholique de Louvain (UCL), Brussels, Belgium  
**A. Thomas, MD, BSc, MBChB, MRCP, FRCPC**, Royal Manchester Children's Hospital, Central Manchester University Hospitals, Manchester, UK  
**A. Thorell, PhD, MD**, Ersta Hospital, Karolinska Institutet, Stockholm, Sweden  
**M. Usami**, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan  
**M. Uyar**, School of Medicine, Ege University, Bornova-Izmir, Turkey  
**N. Vaisman, MD**, Tel-Aviv Sourasky Medical Centre, Tel Aviv University, Tel-Aviv, Israel  
**L. Valentini, MD, PhD**, Dept of Agriculture, University of Applied Sciences - Hochschule Neubrandenburg, Neubrandenburg, Germany  
**M. van Bokhorst-de van der Schueren, PhD, RD**, Dept. of Nutrition and Dietetics, Vrije Universiteit Amsterdam Medical Center, Amsterdam, Netherlands  
**G. van den Berghe, MD, PhD**, Lab. of Intensive Care Medicine, KU Leuven, Leuven, Belgium  
**A. VG. Van Gossom, PhD**, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, UK  
**P. van Leeuwen, MD, PhD**, Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands  
**C. Van Way**, Department of Surgery, University of Missouri Kansas City, Kansas City, Missouri, USA  
**M. Vandewoude**, ZNA Sint Elisabeth, Antwerpen, Belgium  
**E Volpi, MD, PhD**, Division of Geriatric Medicine, UTMB, Galveston, Texas, USA  
**M. von Meyenfeldt, MD, PhD**, Academic Hospital Maastricht, University of Maastricht, Maastricht, Netherlands  
**J. Wahren**, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden  
**D. Waitzberg, MD, PhD**, USP School of Medicine, Sao Paulo, Brazil  
**A. Weimann, MD**, Klinik für Allgemein- und Visceralchirurgie, Leipzig, Germany  
**J. Wernerman, MD, PhD**, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden  
**B. M. Winkhofer-Roob, MD, PhD**, Institute of Molecular Biosciences, Karl-Franzens-Universität Graz, Graz, Austria  
**P. Wischmeyer, MD**, Sch. of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA  
**Z. Zadak, MD, PhD**, Dept. of Gerontology and Metabolic Care, Charles University, Prague-Prag 1, Czech Republic

**T. R. Ziegler, MD**, Emory University Hospital, Atlanta, Georgia, USA

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

*Clinical Nutrition Experimental* is the peer-reviewed open-access official journal of [ESPEN, The European Society for Clinical Nutrition and Metabolism](#). With the aim to stimulate experimental research activities in the field of Clinical Nutrition, the journal welcomes the latest and most exciting experimental articles on methodology, nutrient physiology and metabolism, nutritional neurosciences, nutritional toxicities, nutritional immunology, nutrigenomics, molecular nutrition, vitamins, trace elements, antioxidants, genetics and microbiota. Completing the existing journals: *Clinical Nutrition* and *Clinical Nutrition ESPEN*, CNX will promote methodology and basic science in the field of Clinical Nutrition.

### *Easy Submission Process*

The Editorial Office has implemented an Easy Submission Process. We only ask you that with initial submission the manuscripts are double-spaced (including references, tables, and figure legends) and lines are numbered continuously, beginning in the title page and thus every line has a unique number (Microsoft WORD: /Page Layout>Line Numbers).

All required items below need to be completed in formatting prior to final acceptance of a manuscript. Before submitting your paper to the journal make sure that you have covered all relevant items as indicated on this checklist: [https://www.elsevier.com/\\_\\_data/promis\\_misc/CNX\\_Submission\\_Checklist.docx](https://www.elsevier.com/__data/promis_misc/CNX_Submission_Checklist.docx)

**Full Length Articles.** Should be organized in the following successive sections and manuscript preparation and format information above to be followed: Title Page, Abstract (Background & Aims - Methods - Results - Conclusions). Introduction, Materials and Methods (including statistical considerations and ethical statement), Results, Discussion, Acknowledgements, Statement of Authorship, Conflict of Interest Statement and Funding sources, References; Figure and Table Legends. The Introduction should be limited to 1.5 pages (450 words) and the Discussion to 4 pages (1200 words).

**Review Article.** Should contain at least 2 Figures and 2 Tables to summarize the most important data and/or concepts.

**(Inter)national Guidelines.** Can be submitted after consultation with the Editorial Office ([espenjournals@espen.org](mailto:espenjournals@espen.org)).

**ESPEN Guidelines.** Are submitted in collaboration with the Editorial Office ([espenjournals@espen.org](mailto:espenjournals@espen.org)).

**ESPEN Endorsed Recommendations.** Are submitted in collaboration with the Editorial Office ([espenjournals@espen.org](mailto:espenjournals@espen.org)).

**Letter to the Editor.** Is considered for publication provided it does not contain material that has been submitted or published elsewhere. The text, not including references, must not exceed 450 words. The letter must have no more than five references and one figure or small table and should not be signed by more than three authors. When a letter refers to an article recently published in *Clinical Nutrition Experimental*, the opportunity for reply will be given to the authors of the original article. Such a reply will be published along with the letter. Start the letter with "Dear Editor".

**Editorial.** Are submitted by members of the Editorial Board.

**Short Communications.** Should not contain more than 10 references and organized as Full Length Articles. Maximum 1500 words.

**Opinion Papers.** Should be organized as Full Length articles.

**Educational Papers.** Should be organized as Full Length articles and contain at least 2 Figures and 2 Tables to summarize the most important data and/or concepts.

**Invited Editorial.** Is by invitation from the Editor-in-Chief.

**Randomized Controlled Trials.** Should be organized as Full Length Articles. All Randomized controlled Trials submitted for publication in *Clinical Nutrition Experimental* should include a completed Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist. Please refer to the CONSORT statement website at <http://www.consort-statement.org> for more information. The checklist can also be downloaded from here. You will be asked to upload this completed checklist at the time of submission and this file is mandatory for submission. *Clinical Nutrition Experimental* has adopted the proposal from the [International Committee of Medical Journal Editors \(ICMJE\)](#) which requires, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Clinical trials are defined as "biomedical or health related studies in human beings that follow a defined protocol." In addition to intervention studies, this definition encompasses observational, prevention, quality of life, diagnostic, and screening trials ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)). Any clinical trial for which subject recruitment began after July 1, 2008 must be registered in one of the five ICMJE-approved public trials registries (i.e., [www.clinicaltrials.gov](http://www.clinicaltrials.gov), [www.isrctn.org](http://www.isrctn.org), [www.umin.ac.jp](http://www.umin.ac.jp), [www.trialregister.nl](http://www.trialregister.nl)). Is this study appropriately registered? If so, please report the study ID number and the website where the clinical trial is registered on the title page of the paper. If the study is not registered, authors must do so before the submitted paper will be considered for peer-review. If the study began before July 1, 2008, the initial recruitment date should be reported in the appropriate place in the Materials and Methods section. *Clinical Nutrition Experimental* requires prospective registration of all trials.

**Report.** Should be organized as Full Length Articles and are submitted by chairs of Special Interest Groups (SIG) or are submitted in collaboration with the Editorial Office.

**Meta-analyses.** Should be organized as Full Length Articles. All Meta-analyses submitted for publication in *Clinical Nutrition Experimental* should also include a completed uploaded PRISMA Statement. We have adopted the definitions of systematic review and meta-analysis used by the Cochrane Collaboration. A systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies. Downloadable forms are located at <http://www.prisma-statement.org/>.

## **BEFORE YOU BEGIN**

### **Studies in humans and animals**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association \(Declaration of Helsinki\)](#) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work using the ICMJE Form for Disclosure of Potential Conflicts of Interest <http://icmje.org/conflicts-of-interest>. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please indicate this in the form. See also <https://www.elsevier.com/conflictsofinterest>.

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

#### *Preprints*

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

### **Author contributions**

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. [More details and an example](#)

### **Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

#### *Registration of clinical trials*

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](#) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number



should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

#### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

#### **Copyright**

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

#### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

#### **Open access**

This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

##### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

##### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 1250** for ESPEN members and **USD 2000**, for non-ESPE members, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

#### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

#### *Submit your article*

Please submit your article via <https://www.evis.com/profile/api/navigate/YCLNEX>.

## **PREPARATION**

## NEW SUBMISSIONS

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

### Figures and tables embedded in text

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

## Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

## REVISED SUBMISSIONS

### Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Highlights**

Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

#### *Graphical abstract*

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### *Abbreviations*

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

#### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

### **Artwork**

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

#### *Illustration services*

[Elsevier's WebShop](#) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

#### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

#### **References**

##### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

##### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software.](#)

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/clinical-nutrition-experimental>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

##### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by

the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

#### *Reference style*

References have to be cited in the text by Arabic numerals and numbered in the order in which they are cited. The reference section should be typed double-spaced at the end of the text, following the sample format given below. Abbreviate journal titles according to the List of Journals Indexed in Index Medicus (available from the Superintendent of Documents, US Government Printing Office, Washington, D.C. 20402, USA, DHEW Publication No. (NIH) 91-267; ISSN 0093-3821. Provide all authors' names. Provide article titles and inclusive pages. 'Unpublished data' and 'personal communications' do not qualify as References and should be placed in parentheses in the text. Accuracy of reference data is the responsibility of the author. Refer to the Vancouver style of citation with your reference manager program or use the suggestion below.

Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. <http://dx.doi.org/10.17632/xwj98nb39r.1>.

#### *Sample references*

##### Article in a journal

1. Cummings J H, MacFarlane G T. Role of intestinal bacteria in nutrient metabolism. *Clin Nutr* 1997; 16: 3–11.

##### Book

2. McLaren D S, Meguid M M. *Nutrition and its disorders*, 4th edn. Edinburgh: Churchill Livingstone, 1988.

##### Chapter in a book

3. Goodwin S C, Liu S. Radiologic techniques for enteral access. In: Rombeau J L, Rolandelli R H, Eds. *Enteral and tube feeding*, 3rd edn. Philadelphia: W B Saunders, 1997: 193–206.

##### Website

4. U.S. positions on selected issues at the third negotiating session of the Framework Convention on Tobacco Control. Washington, D.C.: Committee on Government Reform, 2002. (Accessed March 4, 2002, at [http://www.house.gov/reform/min/inves\\_tobacco/index\\_accord.htm](http://www.house.gov/reform/min/inves_tobacco/index_accord.htm).)

##### Online journal article

5. Tenesa A, Noble C, Satsangi J et al. Association of DLG 5 and inflammatory bowel disease across human populations. *Eur Journal Hum Genet* 2006: published online Jan 4. DOI:10.1038/sj.ejhg.5201516

### **Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

### **Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)

For any further information please visit our customer support site at <https://service.elsevier.com>.

### **AFTER ACCEPTANCE**

#### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>